Genmab is the latest company to join an escalating arms race in antibody-drug conjugates, challenging AbbVie’s lead in ovarian cancer treatment.
Competition in the field of antibody-drug conjugates (ADC) is now in full swing, with this week seeing a flurry of activity in ovarian cancer.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
